Contract terminated with Site Management Organization

This single arm, prospective, observational study will assess the correlation between the time from start of chemotherapy to the start of Avastin (bevacizumab) treatment with progression-free survival in patients with previously untreated metastatic colorectal cancer. Patients will be followed for up to 12 months after progressive disease occurs.

Inclusion Criteria:

• Adult patients, >/= the 18 years of age
• Previously untreated metastatic colorectal cancer
• Scheduled to start 1st line chemotherapeutic treatment
• ECOG performance status 0-1

Exclusion Criteria:

• Any conditions included in contraindication list for Avastin
• Prior chemotherapy for metastatic colorectal cancer
• Adjuvant/neoadjuvant chemotherapy or radio-chemotherapy of non-metastatic colorectal cancer completed <6 months prior to treatment start

First-line treatment with Avastin